Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review

30 Citations (Scopus)


Over the last decade, the discovery of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) has increased the treatment options for patients with type 2 diabetes mellitus (T2DM). GLP-1 RAs mimic the effects of native GLP-1, which increases insulin secretion, inhibits glucagon secretion, increases satiety and slows gastric emptying. This review evaluates the phase III trials for all approved GLP-1 RAs and reports that all GLP-1 RAs decrease HbA1c, fasting plasma glucose, and lead to a reduction in body weight in the majority of trials. The most common adverse events are nausea and other gastrointestinal discomfort, while hypoglycaemia is rarely reported when GLP-1 RAs not are combined with sulfonylurea or insulin. Treatment options in the near future will include co-formulations of basal insulin and a GLP-1 RA.

Original languageEnglish
JournalExpert Review of Clinical Pharmacology
Issue number2
Pages (from-to)241-65
Number of pages25
Publication statusPublished - Nov 2016


  • Animals
  • Blood Glucose
  • Diabetes Mellitus, Type 2
  • Glucagon
  • Glucagon-Like Peptide 1
  • Glucagon-Like Peptide-1 Receptor
  • Humans
  • Hypoglycemic Agents
  • Insulin
  • Journal Article
  • Review


Dive into the research topics of 'Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review'. Together they form a unique fingerprint.

Cite this